Extensive research on CD16 (FcγRIIIa) and its role in tumor control through ADCC with both therapeutically administered47,66,67 and naturally produced68 antibodies prompted us to characterize CD16 expression on Vδ2 T cells isolated from healthy human peripheral blood mononuclear cells and assess the potential for CD16 to serve as a biomarker for donor selection. Here, FCGR3A is linked to neoplasm.